

研究成果の刊行に関する一覧表

< ガイドライン >

- ・脳腫瘍診療ガイドライン2019年版（金原出版株式会社）
- ・ミスマッチ修復機能欠損固形がんに対する診断および免疫チェックポイント阻害薬を用いた診療に関する暫定的臨床提言

< 論文 >

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Mishima S, Muro K (著者 16名中9番目), Nishiyama H (著者 16名中11番目), Kodera Y (著者 16名中15番目) et al.	Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition.	Int J Clin Oncol	25	217-239	2020
Naito Y, Nishiyama H (著者 26名中12番目), Kodera Y (著者 16名中24番目), et al.	Japan society of clinical oncology/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and periatric patients with neurotropic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology/oncology.	Int J Clin Oncol	25	403-417	2020
Yoshino T, Pentheroudakis G, Kodera Y (著者 19人、15番目) et al.	JSCO/ESMO/ASCO/JSMO/TOS: International expert consensus recommendations for tumor-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.	Ann Oncol	Epub ahead of print.		2020
Sassa N, Yokoyama Y, Kodera Y (著者 9名中8番目) et al.	Clinical characteristics and surgical outcomes of retroperitoneal tumors: a comprehensive data collection from multiple departments.	Int J Clin Oncol	Epub ahead of print.		2020
Japanese Gastric Cancer Association (corresponding author: Y. Kodera).	Japanese gastric cancer treatment guidelines 2018 (5 th edition).	Gastric Cancer	Epub ahead of print.		2020
Mizuno K, Ito T, Kodera Y (著者 23名中16番目) et al.	Real world data of injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies.	J Gastr oenterol	Epub ahead of print.		2020

Okada N, Iwama S, Kodera Y (著者 33 名中 24 番目), et al.	Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-pragamed cell death-1 antibodies: a prospective study.	Br J Cancer	122(6)	771-777	2020
Haga Y, Hiki N, Kinoshita T, Ojima T, Nabeya Y, Kuwabara S, Seto Y, Yajima K, Takeuchi H, Yoshida K, Kodera Y , Fujiwara Y, Baba H.	Treatment option of endoscopic stent insertion or gastrojejunostomy for gastric outlet obstruction due to gastric cancer: a propensity-matched analysis.	Gastric Cancer	Epub ahead of print		2020
Nakagawa N, Yamada S, Sonohara F, Takami H, Hayashi M, Kanda M, Kobayashi D, Tanaka C, Nakayama G, Koike M, Fujiwara M, Kodera Y .	Clinical implications of Naples prognostic score in patients with resected pancreatic cancer.	Ann Surg Oncol	27(3)	887-895	2020
Sunagawa Y, Yamada S, Sato Y, Morimoto D, Sonohara F, Takami H, Inokawa Y, Hayashi M, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y .	Novel prognostic implications of DUPAN-2 in the era of initial systemic therapy for pancreatic cancer.	Ann Surg Oncol	Epub ahead of print		2019
Misawa K, Mochizuki Y, Sakai M, Teramoto H, Morimoto D, Nakayama H, Tanaka N, Matuuio T, Ito Y, Ito S, Tanaka K, Uemura K, Morita S, Kodera Y .	Randomized clinical trial of extensive intraoperative peritoneal lavage versus standard treatment for resectable advanced gastric cancer (CCOG1102 trial)	Br J Surg	106(12)	1602-1610	2019
Hattori N, Nakayama G, Uehara K, Aiba T, Ishigure K, Sakamoto E, Tojima Y, Kanda M, Kobayashi D, Tanaka C, Yanada S, Koike M, Fujiwara M, Nagino M, Kodera Y .		Int J Clin Oncol	25(1)	118-125	2020
Muro K , Lordick F, Tsushima T, Pentheroudakis G, Baba E, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Kato K, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Nakajima TE, Shitara K, Kawakami H, Narita Y, Yoshino T, Van Cutsem E, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.	Ann Oncol	30	34-43	2019
Muro K , Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Kato K, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Nakajima TE, Shitara K, Kawakami H, Tsushima T, Yoshino T, Lordick F, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.	Ann Oncol	30	19-33	2019
Mitani S, Taniguchi H, Sugiyama	The impact of the Glasgow	Ther			2019

K, Masuishi T, Honda K, Narita Y, Kadowaki S, Ura T, Ando M, Tajika M, Yatabe Y, Muro K	Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with <i>BRAF</i> V600E mutation	Adv Med Oncol eCollection			
Muro K , Jen MH, Cheng R	Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data.	Cancer Manag Res	20	2261-2267	2019
Watari J, Mitani S, Ito C, Tozawa K, Tomita T, Oshima T, Fukui H, Kadowaki S, Natsume S, Senda Y, Tajika M, Hara K, Yatabe Y, Shimizu Y, Muro K , Morimoto T, Hirota S, Das KM, Miwa H:	Molecular alterations and PD-L1 Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features.	Sci Rep	9	10526	2019
Honda K, Kadowaki S, Kato K, Hanai N, Hasegawa Y, Yatabe Y, Muro K .	Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.	Invest New Drugs	37	791-795	2019
Fujii S, Yoshino T, Yamazaki K, Muro K , Yamaguchi K, Nishina T, Yuki S, Shinozaki E, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K	Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing.	Biomed Rep	11	171-180	2019
Hashiguchi Y, Muro K , Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kinugasa Y, Murofushi K, Nakajima TE, Oka S, Tanaka T, Taniguchi H, Tsuji A, Uehara K, Ueno H, Yamanaka T, Yamazaki K, Yoshida M, Yoshino T, Itabashi M, Sakamaki K, Sano K, Shimada Y, Tanaka S, Uetake H, Yamaguchi S, Yamaguchi N, Kobayashi H, Matsuda K, Kotake K, Sugihara K	Japanese Society for Cancer of the Colon and Rectum: Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer.	Int J Clin Oncol	25	1-42	2020
Mishima S, Taniguchi H, Akagi K, Baba E, Fujiwara Y, Hirasawa A, Ikeda M, Maeda O, Muro K , Nishihara H, Nishiyama H, Takano T, Tsuchihara K, Yatabe Y, Kodera Y, Yoshino T	Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society	Int J Clin Oncol	25	217-239	2020

	of Medical Oncology, First Edition.				
Nakajima TE, Yamaguchi K, Boku N, Hyodo I, Mizusawa J, Hara H, Nishina T, Sakamoto T, Shitara K, Shinozaki K, Katayama H, Nakamura S, Muro K , Terashima M	Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G).	Gastric Cancer	Epub ahead of print		2020
Makiyama A, Sukawa Y, Kashiwada T, Kawada J, Hosokawa A, Horie Y, Tsuji A, Moriwaki T, Tanioka H, Shinozaki K, Uchino K, Yasui H, Tsukuda H, Nishikawa K, Ishida H, Yamanaka T, Yamazaki K, Hironaka S, Esaki T, Boku N, Hyodo I, Muro K	Randomized, phase II study of trastuzumab beyond progression in patients with HER2- positive advanced gastric or gastro-esophageal junction cancer: WJOG7112G (T-ACT Study).	J Clin Oncol	JCO19 03077		2020
Koujima T, Tazawa H, Ieda T, Araki H, Fushimi T, Shoji R, Kuroda S, Kikuchi S, Yoshida R, Umeda Y, Teraishi F, Urata Y, Mizuguchi H, Fujiwara T .	Oncolytic virus-mediated targeting of the ERK signaling pathway inhibits invasive propensity in human pancreatic cancer.	Mol Ther Oncolytics,	17	-107-117	2020
Shirakawa Y, Noma K, Maeda N, Tanabe S, Sakurama K, Fujiwara T .	Microanatomy-based standardization of left upper mediastinal lymph node dissection in thoracoscopic esophagectomy in the prone position.	Surg Endosc	Epub ahead of print		2020
Hashimoto M, Shiwakawa Y, Maeda N, Tanabe S, Noma K, Sakurama K, Katsui K, Nishizaki M, Fujiwara T .	Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer.	Esophagus	17	127-134	2020
Kanaya N, Kuroda S, Kakiuchi Y, Kumon K, Tsumura T, Hashimoto M, Morihiro T, Kubota T, Aoyama K, Kikuchi S, Nishizaki M, Kagawa S, Tazawa H, Mizuguchi H, Urata Y, Fujiwara T .	Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy With Anti-PD1 Antibody	Mol Ther	28(3)	794-804	2020
Sakamoto S, Kagawa S, Kuwada K, Ito A, Kajioka H, Kakiuchi Y, Watanabe M, Kagawa T, Yoshida R, Kikuchi S, Kuroda S, Tazawa H, Fujiwara T .	Intraperitoneal cancer-immune microenvironment promotes peritoneal dissemination of gastric cancer.	Oncoimmunology	8(12)	e1671760	2019
Ieda T, Tazawa H, Okabayashi H, Yano S, Shigeyasu K, Kuroda S, Ohara T, Noma K, Kishimoto H, Nishizaki M, Kagawa S, Shirakawa Y, Saitou T, Imamura T, Fujiwara T .	Visualization of epithelial-mesenchymal transition in an inflammatory microenvironment-colorectal cancer network.	Sci Rep	9(1)	16378	2019
Hirata K, Imamura M, Fujiwara T, Fukui T, Furukawa T, Gotoh M, Hakamada K, Ishiguro M, Kakeji Y, Konno H, Miyata H, Mori M, Okita K, Sato M, Shibata A, Takemasa I, Unno M,	Current status of site-specific registry system for the clinical researches: aiming for future contribution by the assessment of present medical care.	Int J Clin Oncol	24(9)	1161-1168	2019

Yokoi K, Nishidate T, Nishiyama M, Fujiwara T.					
Matsueda K, Kanzaki H, Matsueda K, Nasu J, Yoshioka M, Nakagawa M, Inoue M, Inaba T, Imagawa A, Takatani M, Takenaka R, Suzuki S, Tomoda J, Yagi T, Fujiwara T , Tanaka T, Okada H.	The clinicopathological differences of sporadic non-ampullary duodenal epithelial neoplasm depending on tumor location.	J Gastroenterol Hepatol	34(9)	1540-1544	2019
Asano N, Takeshima H, Yamashita S, Takamatsu H, Hattori N, Kubo T, Yoshida A, Kobayashi E, Nakayama R, Matsumoto M, Nakamura M, Ichikawa H, Kawai A , Kondo T, Ushijima	T.Epigenetic reprogramming underlies efficacy of DNA demethylation therapy in osteosarcomas.	Sci Rep.	9(1)	20360	2019
Doi T, Matsubara N, Kawai A , Naka N, Takahashi S, Uemura H, Yamamoto N	Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs.				2019
Tanaka K, Mizusawa J, Naka N, Kawai A , Katagiri H, Hiruma T, Matsumoto Y, Tsuchiya H, Nakayama R, Hatano H, Emori M, Watanuki M, Yoshida Y, Okamoto T, Abe S, Asanuma K, Yokoyama R, Hiraga H, Yonemoto T, Morii T, Ae K, Nagano A, Yoshikawa H, Fukuda H, Ozaki T, Iwamoto Y.	Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities: Japan Clinical Oncology Group study JCOG0304.	BMC Cancer.	19(1)	890	2019
Nakagawa M, Nakatani F, Matsunaga H, Seki T, Endo M, Ogawara Y, Machida Y, Katsumoto T, Yamagata K, Hattori A, Fujita S, Aikawa Y, Ishikawa T, Soga T, Kawai A , Chuman H, Yokoyama N, Fukushima S, Yahiro K, Kimura A, Shimada E, Hirose T, Fujiwara T, Setsu N, Matsumoto Y, Iwamoto Y, Nakashima Y, Kitabayashi I.	Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.	Oncogene.	38(42)	6835-6849	2019
Kobayashi E, Naito Y, Asano N, Maejima A, Endo M, Takahashi S, Megumi Y, Kawai A .	Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes.	Jpn J Clin Oncol.	49(10)	938-946	2019
Sanada Y, Harada M, Kunitomi C, Kanatani M, Izumi G, Hirata T, Fujii T, Suzuki N, Morishige KI, Aoki D, Irahara M, Tsugawa K, Tanimoto M, Nishiyama H, Hosoi H, Sugiyama K, Kawai A , Osuga Y.	A Japanese nationwide survey on the cryopreservation of embryos, oocytes and ovarian tissue for cancer patients.	J Obstet Gynaecol Res.	45(10)	2021-2028	2019
Nishida Y, Kawai A , Toguchida J, Ogose A, Ae K, Kunisada T, Matsumoto Y, Matsunobu T, Takahashi K, Nishida K, Ozaki T.	Clinical features and treatment outcome of desmoid-type fibromatosis: based on a bone and soft tissue tumor registry in Japan.	Int J Clin Oncol.	24(11)	1498-1505	2019
Sekimizu M, Ogura K, Yasunaga H, Matsui H, Tanaka S, Inagaki K,	Development of nomograms for prognostication of patients	BMC Cancer.	19(1)	657	2019

<u>Kawai A</u>	with primary soft tissue sarcomas of the trunk and extremity: report from the Bone and Soft Tissue Tumor Registry in Japan.				
Toki S, Kobayashi E, Yoshida A, Ogura K, Wakai S, Yoshimoto S, Yonemori K, <u>Kawai A</u> .	A clinical comparison between dedifferentiated low-grade osteosarcoma and conventional osteosarcoma.	Bone Joint J.	101-B(6)	745-752	2019
Yoshida A, Arai Y, Tanzawa Y, Wakai S, Hama N, <u>Kawai A</u> , Shibata T.	KMT2A (MLL) fusions in aggressive sarcomas in young adults.	Histopathology.	75(4)	508-516	2019
Makise N, Sekimizu M, Kobayashi E, Yoshida H, Fukayama M, Kato T, <u>Kawai A</u> , Ichikawa H, Yoshida A	Low-grade endometrial stromal sarcoma with a novel MEAF6-SUZ12 fusion.	Virchows Arch	475(4)	527-531	2019
Asano N, Matsuzaki J, Ichikawa M, Kawauchi J, Takizawa S, Aoki Y, Sakamoto H, Yoshida A, Kobayashi E, Tanzawa Y, Nakayama R, Morioka H, Matsumoto M, Nakamura M, Kondo T, Kato K, Tsuchiya N, <u>Kawai A</u> , Ochiya T.	A serum microRNA classifier for the diagnosis of sarcomas of various histological subtypes.	Nat Commun.	10(1)	1299	2019
Urakawa H, Mizusawa J, Tanaka K, Eba J, Hiraga H, <u>Kawai A</u> , Nishida Y, Hosaka M, Iwamoto Y, Fukuda H, Ozaki T	A randomized phase III trial of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group Study JCOG1610.	Jpn J Clin Oncol.	49(4)	379-382	2019
Takeuchi A, Nomura A, Yamamoto N, Hayashi K, Igarashi K, Tandai S, <u>Kawai A</u> , Matsumine A, Miwa S, Nishida Y, Nakamura T, Terauchi R, Hoshi M, Kunisada T, Endo M, Yoshimura K, Murayama T, Tsuchiya H.	Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol.BMC	BMC Musculoskelet Disord.	20(1)	68	2019
Tashiro K, Arikawa M, Kagaya Y, Kobayashi E, <u>Kawai A</u> , Miyamoto S.	Flap reconstruction after groin and medial thigh sarcoma resection reduces the risk of lower-extremity lymphedema.	J Plast Reconstr Aesthet Surg.	72(4)	685-710	2019
Yamazaki F, Nakatani F, Asano N, Wakai S, Sekimizu M, Mitani S, Kubo T, <u>Kawai A</u> , Ichikawa H, Yoshida A.	Novel NTRK3 Fusions in Fibrosarcomas of Adults.	Am J Surg Pathol.	43(4)	523-530	2019
Oyama R, Kito F, Qiao Z, Sakumoto M, Shiozawa K, Toki S, Yoshida A, <u>Kawai A</u> , Kondo T.	Establishment of novel patient-derived models of dermatofibrosarcoma protuberans: two cell lines, NCC-DFSP1-C1 and NCC-DFSP2-C1.	Vitro Cell Dev Biol Anim.	55(1)	62-73	2019
Koike H, Nishida Y, Kohno K, Shimoyama Y, Motoi T, Hamada	Is immunohistochemical staining for β -catenin the	Hum Pathol.	84	155-163	2019

S, Kawai A , Ogose A, Ozaki T, Kunisada T, Matsumoto Y, Matsunobu T, Ae K, Gokita T, Sakai T, Shimizu K, Ishiguro N.	definitive pathological diagnostic tool for desmoid-type fibromatosis? A multi-institutional study.				
Makise N, Sekimizu M, Konishi E, Motoi T, Kubo T, Ikoma H, Watanabe SI, Okuma T, Hiraoka N, Fukayama M, Kawai A , Ichikawa H, Yoshida A.	H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features.	Mod Pathol.	32(3)	435-445	2019
Tashiro K, Arikawa M, Fukunaga Y, Nakatani F, Kobayashi E, Kawai A , Miyamoto S.	Free latissimus dorsi musculocutaneous flap for external hemipelvectomy reconstruction.	Microsurgery.	39(2)	138-143	2019
Okuma HS, Yonemori K, Narita SN, Sukigara T, Hirakawa A, Shimizu T, Shibata T, Kawai A , Yamamoto N, Nakamura K, Nishida T, Fujiwara Y.	MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial.	Clin Pharmacol Ther.	Epub ahead of print		2020
Frezza AM, Assi T, Lo Vullo S, Ben-Ami E, Dufresne A, Yonemori K, Noguchi E, Siontis B, Ferraro R, Teterycz P, Duffaud F, Ravi V, Vincenzi B, Gelderblom H, Pantaleo MA, Baldi GG, Desar I, Fedenko A, Maki RG, Jones RL, Benjamin RS, Blay JY, Kawai A , Gounder M, Gronchi A, Le Cesne A, Mir O, Czarnecka AM, Schuetze S, Wagner AJ, Adam J, Barisella M, Sbaraglia M, Hornick JL, Meurgey A, Mariani L, Casali PG, Thornton K,	Stacchiotti S. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.	Cancer.	126(1)	98-104	2020
Nagano A, Matsumoto S, Kawai A , Okuma T, Hiraga H, Matsumoto Y, Nishida Y, Yonemoto T, Hosaka M, Takahashi M, Yoshikawa H, Kunisada T, Asanuma K, Naka N, Emori M, Kubo T, Kawashima H, Kawamoto T, Yokoyama R, Tsukushi S, Sato K, Okamoto T, Hiraoka K, Morioka H, Tanaka K, Takagi T, Iwamoto Y, Ozaki T.	Osteosarcoma in patients over 50 years of age: Multi-institutional retrospective analysis of 104 patients.	J Orthop Sci.	25(2)	319-323	2020
Yoshida A, Wakai S, Ryo E, Miyata K, Miyazawa M, Yoshida KI, Motoi T, Ogawa C, Iwata S , Kobayashi E, Watanabe SI, Kawai A , Mori T.	Expanding the Phenotypic Spectrum of Mesenchymal Tumors Harboring the EWSR1-CREM Fusion	Am J Surg Pathol.	43(12)	1622-1630	2019
Hirata M, Asano N, Katayama K, Yoshida A, Tsuda Y, Sekimizu M, Mitani S, Kobayashi E,	Integrated exome and RNA sequencing of dedifferentiated liposarcoma.	Nat Commun.	10(1)	5683	2019

Komiyama M, Fujimoto H, Goto T, Iwamoto Y, Naka N, <u>Iwata S</u> , Nishida Y, Hiruma T, Hiraga H, Kawano H, Motoi T, Oda Y, Matsubara D, Fujita M, Shibata T, Nakagawa H, Nakayama R, Kondo T, Imoto S, Miyano S, Kawai A , Yamaguchi R, Ichikawa H, Matsuda K.					
Yoshida KI, Nakano Y, Honda-Kitahara M, Wakai S, Motoi T, Ogura K, Sano N, Shibata T, Okuma T, <u>Iwata S</u> , Kawai A , Ichimura K, Yoshida A.	Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone.	Mod Pathol.	32(12)	1751-1761	2019
Tsuda Y, Hirata M, Katayama K, Motoi T, Matsubara D, Oda Y, Fujita M, Kobayashi H, Kawano H, Nishida Y, Sakai T, Okuma T, Goto T, Ogura K, Kawai A , Ae K, Anazawa U, Suehara Y, <u>Iwata S</u> , Miyano S, Imoto S, Shibata T, Nakagawa H, Yamaguchi R, Tanaka S, Matsuda K.	Massively parallel sequencing of tenosynovial giant cell tumors reveals novel CSF1 fusion transcripts and novel somatic CBL mutations.	Int J Cancer.	145(12)	3276-3284	2019
Kinoshita H, Orita S, Yonemoto T, Ishii T, <u>Iwata S</u> , Kamoda H, Tsukanishi T, Inage K, Abe K, Inoue M, Norimoto M, Umimura T, Fujimoto K, Shiga Y, Kanamoto H, Furuya T, Takahashi K, Ohtori S.	J Med Case Rep.		13(1)	116	2019
Kobayashi H, <u>Iwata S</u> , Wakamatsu T, Hayakawa K, Yonemoto T, Wasa J, Oka H, Ueda T, Tanaka S.	Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study.	Cancer.	126(6)	1253-1263	2020
Oyama R, Kito F, Takahashi M, Hattori E, Noguchi R, Takai Y, Sakumoto M, Qiao Z, Toki S, Sugawara M, Tanzawa Y, Kobayashi E, Nakatani F, <u>Iwata S</u> , Yoshida A, Kawai A , Kondo T.	Establishment and characterization of patient-derived cancer models of malignant peripheral nerve sheath tumors.	Cancer Cell Int.	20	58	2019
Ogura K, Uehara K, Akiyama T, Shinoda Y, <u>Iwata S</u> , Tsukushi S, Kobayashi E, Hirose T, Yonemoto T, Endo M, Tanzawa Y, Nakatani F, Kawano H, Tanaka S, Kawai A .	Minimal clinically important differences in Toronto Extremity Salvage Score for patients with lower extremity sarcoma.	J Orthop Sci.	(2)	315-318	2020
Yoshimatsu Y, Noguchi R, Tsuchiya R, Sei A, Sugaya J, <u>Iwata S</u> , Sugiyama M, Yoshida A, Kawai A , Kondo T	Establishment and characterization of NCC-ssRMS1-C1: a novel patient-derived	Hum Cell.			2020

	spindle-cell/sclerosing rhabdomyosarcoma cell line.				
Yoshimatsu Y, Noguchi R, Tsuchiya R, Sei A, Sugaya J, <u>Iwata S</u> , Yoshida A, <u>Kawai A</u> , Kondo T.	Establishment and characterization of NCC-SS3-C1: a novel patient-derived cell line of synovial sarcoma.	Hum Cell			2020
Yoshimatsu Y, Noguchi R, Tsuchiya R, Kito F, Sei A, Sugaya J, Nakagawa M, Yoshida A, <u>Iwata S</u> , <u>Kawai A</u> , Kondo T.	Establishment and characterization of NCC-CDS2-C1: a novel patient-derived cell line of CIC-DUX4 sarcoma.	Hum Cell.	33(2)	427-436	2020
<u>Yoko Katoh</u> , Yasushi Goto, Wataru Munakata, Taro Shibata, Takuro Sakurai, Shintaro Iwata, <u>Akira Kawai</u> , Toshirou Nishida.	Meet the Expert on Rare Cancer - Social Contribution by Rare Cancer Center Annals of Oncology:30.		Issue Suppl-6		2019
<u>Yoko Katoh</u> , <u>Akira Kawai</u> , Taro Shibata, Yasushi Goto, Tatsuya Suzuki, Shintaro Iwata, Kan Yonemori, Wataru Munakata, Eriko Satomi, Akihiko Yoshida, Takuro Sakurai, Tomoko Takayama, Takahiro Higashi, Tosirou Nishida.	Rare Cancer Center - All Activities for Rare Cancer Patients!Annals of Oncology:30		Issue Suppl-6		2019
Tsuruta S, Ohishi Y, Fujiwara M, Ihara E, Ogawa Y, Oki E, Nakamura M, <u>Oda Y</u> .	Gastric hepatoid adenocarcinomas are a genetically heterogenous group; most tumors show 'chromosomal instability,' but 'MSI tumors do exist.	Hum Pathol	88	27-38	2019
Yamada Y, Kohashi K, Kinoshita I, Yamamoto H, Iwasaki T, Yoshimoto M, Ishihara S, Toda Y, Itou Y, Koga Y, Hashisako M, Nozaki Y, Kiyozawa D, Kitahara D, Inoue T, Mukai M, Honda Y, Toyokawa G, Tsuchihashi K, Matsushita Y, Fushimi F, Taguchi K, Tamiya S, Oshiro Y, Furue M, Nakashima Y, Suzuki S, Iwaki T, <u>Oda Y</u> .	Clinicopathological review of solitary fibrous tumors: dedifferentiation is a major cause of patient death.	Virchows Arch	475(4)	467-477	2019
Yamamoto H, Nozaki Y, Kohashi K, Kinoshita I, <u>Oda Y</u> .	Diagnostic utility of pan-Trk immunohistochemistry for inflammatory myofibroblastic tumors.	Histopathology.	76(5)	774-778	2019
Hirata M, Asano N, Katayama K, Yoshida A, Tsuda Y, Sekimizu M, Mitani S, Kobayashi E, Komiyama M, Fujimoto H, Goto T, Iwamoto Y, Naka N, Iwata S, Nishida Y, Hiruma T, Hiraga H, Kawano H, Motoi T, <u>Oda Y</u> , Matsubara D, Fujita M, Shibata T, Nakagawa H, Nakayama R, Kondo T, Imoto S, Miyano S,	Integrated exome and RNA sequencing of dedifferentiated liposarcoma.	Nat Commun.	10(1)	5683	2019

Kawai A, Yamaguchi R, Ichikawa H, Matsuda K.					
Ito T, Kaku-Ito Y, Murata M, Ichiki T, Kuma Y, Tanaka Y, Ide T, Ohno F, Wada-Ohno M, Yamada Y, <u>Oda Y</u> , Furue M.	Intra- and Inter-Tumor BRAF Heterogeneity in Acral Melanoma: An Immunohistochemical Analysis	Int J Mol Sci.	20(24)	6191	2019
Ito T, Takeda A, Fujiwara K, Hasegawa E, Nakao S, Ohishi Y, <u>Oda Y</u> , Yoshikawa H, Sonoda KH.	Risk factors for failure of vitrectomy cell block technique in cytological diagnosis of vitreoretinal lymphoma.	Graefes Arch Clin Exp Ophthalmol.	257(5)	1029-1036	2019
Kohsaka S, Tatsuno K, Ueno T, Nagano M, Shinozaki-Ushiku A, Ushiku T, Takai D, Ikegami M, Kobayashi H, Kage H, Ando M, Hata K, Ueda H, Yamamoto S, Kojima S, Oseto K, Akaike K, Suehara Y, Hayashi T, Saito T, Takahashi F, Takahashi K, Takamochi K, Suzuki K, Nagayama S, <u>Oda Y</u> , Mimori K, Ishihara S, Yatomi Y, Nagase T, Nakajima J, Tanaka S, Fukayama M, Oda K, Nangaku M, Miyazono K, Miyagawa K, Aburatani H, Mano H.	Comprehensive Assay for the Molecular Profiling of Cancer by Target Enrichment From Formalin-Fixed Paraffin-Embedded Specimens.	Cancer Sci	110(4)	1464-1479	2019
Miki M, Oono T, Fujimori N, Takaoka T, Kawabe K, Miyasaka Y, Ohtsuka T, Saito D, Nakamura M, Ohkawa Y, <u>Oda Y</u> , Suyama M, Ito T, Ogawa Y.	CLEC3A, MMP7, and LCN2 as novel markers for predicting recurrence in resected G1 and G2 pancreatic neuroendocrine tumors.	Cancer Med.	8(8)	3748-3760	2019
Murayama R, Nishie A, Hida T, Baba S, Inokuchi J, <u>Oda Y</u> , Honda H.	Uptake of 18F-FDG in Adrenal Adenomas Is Associated With Unenhanced CT Value and Constituent Cells.	Clin Nucl Med.	44(12)	943-948	2019
Souzaki R, Kawakubo N, Matsuura T, Yoshimaru K, Koga Y, Takemoto J, Shibui Y, Kohashi K, Hayashida M, <u>Oda Y</u> , Ohga S, Taguchi T.	Navigation surgery using indocyanine green fluorescent imaging for hepatoblastoma patients.	Pediatr Surg Int.	35(5)	551-557	2019
Tsuda Y, Hirata M, Katayama K, Motoi T, Matsubara D, <u>Oda Y</u> , Fujita M, Kobayashi H, Kawano H, Nishida Y, Sakai T, Okuma T, Goto T, Ogura K, Kawai A, Ae K, Anazawa U, Suehara Y, Iwata S, Miyano S, Imoto S, Shibata T, Nakagawa H, Yamaguchi R, Tanaka S, Matsuda K.	Massively parallel sequencing of tenosynovial giant cell tumors reveals novel CSF1 fusion transcripts and novel somatic CBL mutations.	Int J Cancer	145(12)	3276-3284	2019
Yoshimura M, Kinoshita Y, Hamasaki M, Matsumoto S, Hida T, <u>Oda Y</u> , Iwasaki A, Nabeshima K.	Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial	Lung Cancer	130	187-193	2019

	hyperplasia.				
Hori Y, Yamamoto H, Nozaki Y, Fujiwara M, Taguchi K, Nishiyama K, Nakamura S, <u>Oda Y.</u>	Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.	Hum Pathol.	96	67-78	2019
Okumura Y, Kohashi K, Tanaka Y, Kato M, Maehara Y, Ogawa Y, <u>Oda Y.</u>	Activation of the Akt/mammalian target of rapamycin pathway in combined hepatocellular carcinoma and cholangiocarcinoma: significant correlation between p-4E-BP1 expression in cholangiocarcinoma component and prognosis.	Virchows Arch.	Epub ahead of print		2020
Tsuruta S, Kohashi K, Yamada Y, Fujiwara M, Koga Y, Ihara E, Ogawa Y, Oki E, Nakamura M, <u>Oda Y.</u>	Solid-type poorly differentiated adenocarcinoma of the stomach: Deficiency of mismatch repair and SWI/SNF complex.	Cancer Sci.	111(3)	1008-1019	2020
Yoshimoto M, Yamada Y, Ishihara S, Kohashi K, Toda Y, Ito Y, Yamamoto H, Furue M, Nakashima Y, <u>Oda Y.</u>	Comparative Study of Myxofibrosarcoma With Undifferentiated Pleomorphic Sarcoma: Histopathologic and Clinicopathologic Review,	Am J Surg Pathol.	44(1)	87-97	2020
Basturk O, Weigelt B, Adsay V, Benhamida JK, Askan G, Wang L, Arcila ME, Zamboni G, Fukushima N, Gularte-Mérida R, Da Cruz Paula A, Selenica P, Kumar R, Pareja F, Maher CA, Scholes J, <u>Oda Y</u> , Santini D, Doyle LA, Petersen I, Flucke U, Koelsche C, Reynolds SJ, Yavas A, Deimling AV, Reis-Filho JS, Klimstra DS.	Sclerosing epithelioid mesenchymal neoplasm of the pancreas - a proposed new entity.	Mod Pathol.	33 (3)	456-467	2020
Ito T, Kaku-Ito Y, Murata M, Furue K, Shen C, <u>Oda Y</u> , Furue M.	Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival.	J Clin Med.	9(3)		2020
Narazaki T, Shiratsuchi M, Matsushima T, Tsuda M, Tsukamoto Y, Muta H, Masuda T, Kimura D, Takamatsu A, Yamamoto H, <u>Oda Y</u> , Miyoshi H, Ohshima K, Matsuda Y, Sakamoto R, Nakashima Y, Ogawa Y.	Clinico-pathological Characteristics of Primary Adrenal Lymphomas - Potential Efficacy of Autologous Stem Cell Transplantation.	Leuk Lymphoma.		1-3	2020
Ohmura H, Ito M, Uchino K, Okada C, Tanishima S, Yamada Y, Momosaki S, Komoda M, Kuwayama M, Yamaguchi K, Okumura Y, Nakano M, Tsuchihashi K, Isobe T, Ariyama H, Kusaba H, <u>Oda Y</u> , Akashi K, Baba E.	Methylation of drug resistance-related genes in chemotherapy-sensitive Epstein-Barr virus-associated gastric cancer.	FEBS Open Bio.	10(1)	147-157	2020

Ueda T , Koga Y , Yoshikawa H, Tanabe M, Yamana K, Oba Y, Nakashima K, Ono H, Ichimura T, Hasegawa S, Kato W, Kobayashi T, Nakayama H, Sakai Y, Yoshitake T, Ohga S, <u>Oda Y</u> , Suzuki S, Sonoda K, Ohga S.	Survival and Ocular Preservation in a Long-Term Cohort of Japanese Patients With Retinoblastoma.	BMC Pediatr	20 (1)	37	2020
Yahiro K, Matsumoto Y, Yamada H, Endo M, Setsu N, Fujiwara T, Nakagawa M, Kimura M, Shimada E, Okada S, <u>Oda Y</u> , Nakashima Y.	Activation of TLR4 Signaling Inhibits Progression of Osteosarcoma by Stimulating CD8-positive Cytotoxic Lymphocytes.	Cancer Immunol Immunother.	69(5)	745-758	2020
Yamamoto M, Yoshida Y, Tuneyoshi M, Gion T, Tominaga Y, Koga Y, <u>Oda Y</u> .	"Gastric Perivascular Epithelioid Cell Tumor: A Case Report"	Ann Case Report	11	239	2020
Yugawa K, Yoshizumi T, Kohashi K, Kurihara T, Yoshiya S, Takeishi K, Itoh S, Harada N, Ikegami T, Soejima Y, <u>Oda Y</u> , Mori M.	Solitary fibrous tumor in the liver: case report and literature review.	Surg Case Rep	5(1):	68	2019
Izuwa A, Toyokawa G, Shoji F, Yamazaki K, Momosaki S, Furuya K, Yamada Y, <u>Oda Y</u> , Takeo S.	First Case of a Primary Lung Granulosa Cell Tumor With a Mutation in the Forkhead Box L2 Gene.	J Thorac Oncol	14(5)	e100-e102	2019
Masuda Y, Tsukamoto Y, Zenitani M, <u>Oda Y</u> , Kinoshita I, Kohashi K, Takemoto J, Hirota S, Shibata A, Koda T, Takeshima Y.	A newborn case of jejunal ALK-negative inflammatory myofibroblastic tumor with ETV6-NTRK3 fusion. <i>Pediatr</i>	Blood Cancer.	66(10)	e27902	2019
Miki K, Yoshimoto K, Yamada Y, Kabashima A, Kuga D, <u>Oda Y</u> , Iihara K.	Rapid growth of metastatic brain tumor from gastric undifferentiated pleomorphic sarcoma: A case report.	Surg Neurol Int.	10	74	2019
Yorita K, Togashi Y, Nakagawa H, Miyazaki K, Sakata S, Baba S, Takeuchi K, Hayashi Y, Murakami I, Kuroda N, <u>Oda Y</u> , Kohashi K, Yamada Y, Kiyozawa D, Michal M, Michal M.	Vocal cord inflammatory myofibroblastic tumor with mucoid deposits harboring TIMP3-ALK fusion: A potential diagnostic pitfall.	Pathol Int.	69(6)	366-371	2019
Wang H, Yoshizumi T, Itoh S, Ikegami T, Harada N, <u>Oda Y</u> , Mori M.	Retroperitoneal schwannoma preoperatively diagnosed as liver metastasis from colon cancer: A case report	Int J Surg Case Rep.	64	31-34	2019
Iwasaki T, Kohashi K, Ohno M, Taguchi T, <u>Oda Y</u> .	Establishment and Characterization of a Novel Primitive Yolk Sac Tumour Cell Line, C587.	Anticancer Res.	40(2)	759-766	2019
Yugawa K, Kohashi K, Itoh S, Yoshizumi T, Sakamoto I, Tsutsui H, Mori M, <u>Oda Y</u> .	Combined Hepatocellular-Cholangiocarcinoma After Tetralogy of Fallot Repair: A Case Report and Review of Literature.	Pathol Res Pract.	216(5)	152908	2020
Toya M, Yamada Y, Yokoyama R, Taguchi K, Nabeshima K, Isayama T, <u>Oda Y</u> .	Dedifferentiated Low-Grade Central Osteosarcoma With Extensive Cystic Change Initially Treated as a Simple Bone Cyst.	Pathol Res Pract.	152832		2020
Yamasaki F, <u>Sugiyama K</u> et al.	Effect of bevacizumab against	Cancer	8(15)	6519	2019

	cystic components of brain tumors.	Med.		-6527	
日本脳腫瘍学会編集（脳腫瘍診療ガイドライン拡大委員会 委員長 杉山一彦）	脳腫瘍診療ガイドライン 2019 年版	金原出版			2019
Takami H, Sugiyama K , et al.	Intratumoural immune cell landscape in germinoma reveals multipotent lineages and exhibits prognostic significance.	Neuropathol Appl Neurobiol.	46(2)	111-124	2020
Nagumo Y, Nishiyama H et al.	Clinicopathological features of malignant urachal tumor: A hospital-based cancer registry data in Japan.	Int J Urol.	27(2)	157-162	2020
Sanada Y, Nishiyama H , et al.	A Japanese nationwide survey on the cryopreservation of embryos, oocytes and ovarian tissue for cancer patients	J Obstet Gynaecol Res.	45(10)	2021-2028	2019
Tanaka K, Nishiyama H et al.	Characteristics of penile cancer in Japan: An analysis of nationwide hospital-based cancer registry data in International Journal of Urology has the following publication status.	Int J Urol.	Epub ahead of print		2020
Mishima S, Nishiyama H , et al.	Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition.	Int J Clin Oncol.	25(2)	217-239	2020
Matsumoto H, Nishiyama H , et al	Clinical Practice Guidelines for Bladder Cancer 2019 edition by the Japanese Urological Association: Revision working position paper.	Int J Urol.	Epub ahead of print		2020
山口隆大、杉山豊、 神波大己	陰茎癌の診断と治療 特に原発巣について	臨床泌尿器科	73(11)	832-836	2019
Sueta D., Tabata N., Ikeda S., Saito Y., Ozaki K., Sakata K., Matsumura T., Yamamoto-Ibusuki M., Murakami Y., Jodai T., Fukushima S., Yoshida N., Kamba T. , Araki E., Iwase H., Fujii K., Ihn H., Kobayashi Y., Minamino T., Yamagishi M., Maemura K., Baba H., Matsui K., Tsujita K.	Differential predictive factors for cardiovascular events in patients with or without cancer history.	Medicine (Baltimore)	98(44)	e17602	2019
Baba M., Furuya M., Motoshima T., Lang M., Funasaki S., Ma W., Sun HW., Hasumi H., Huang Y., Kato I., Kadomatsu T., Satou Y.,	Schmidt LS., Linehan WM. TFE3 Xp11.2 translocation renal cell carcinoma mouse model reveals novel therapeutic	Mol Cancer Res.	17(8)	1613-1626	2019

Morris N., Karim BO., Ileva L., Kalen JD., Wilan Krisna LA., Hasumi Y., Sugiyama A., Kurahashi R., Nishimoto K., Oyama M., Nagashima Y., Kuroda N., Araki K., Eto M., Yao M., Kamba T. , Suda T., Oike Y.	targets and identifies GPNMB as a diagnostic marker for human disease.				
Kurahashi R., Kadomatsu T., Baba M., Hara C., Itoh H., Miyata K., Endo M., Morinaga J., Terada K., Araki K., Eto M., Schmidt LS., Kamba T. , Linehan WM., Oike Y.	MiR-204-5p: a novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma.	Cancer Sci.	110(6)	1897-1908	2019
Urakawa H, Mizusawa J, Tanaka K, Eba J, Hiraga H, Kawai A, Nishida Y , Hosaka M, Iwamoto Y, Fukuda H, Ozaki T.	A randomized phase III trial of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group Study JCOG1610.	Jpn J Clin Oncol.	49(4)	379-382	2019
Nishida Y , Kawai A, Toguchida J, Ogose A, Ae K, Kunisada T, Matsumoto Y, Matsunobu T, Takahashi K, Nishida K, Ozaki T	Clinical features and treatment outcome of desmoid-type fibromatosis: based on a bone and soft tissue tumor registry in Japan.	Int J Clin Oncol.	24(11)	1498-1505	2019
Nishida Y , Ikuta K.	Treatment of tenosynovial giant-cell tumour types.	Lancet Oncol	20(8)	e399	2019
Nishida Y , Sakai T, Koike H, Ito K.	Pazopanib for progressive desmoid tumours: children, persistent effects, and cost.	Lancet Oncol.	20(10)	e555	2019
Shimizu K, Hamada S, Sakai T, Ito S, Urakawa H, Arai E, Ikuta K, Koike H, Ishiguro N, Nishida Y .	MRI characteristics predict the efficacy of meloxicam treatment in patients with desmoid-type fibromatosis.	J Med Imaging Radiat Oncol.	63(6)	751-757	2019
Milea J.M. Timbergen, Chiara Colombo, Michel Renckens, Hee Sung Kim, Joost van Rosmalen, Sébastien Salas, John T. Mullen, MD, Piergiuseppe Colombo, Yoshihiro Nishida , MD, Erik A.C. Wiemer, Cornelis Verhoef, Stefan Sleijfer, Alessandro Gronchi, Dirk J. Grünhagen.	The prognostic role of β -catenin mutations in desmoid-type fibromatosis undergoing resection only: a meta-analysis of individual patient data.	Ann Surg.			2019
Sassa N, Yokoyama Y, Nishida Y , Yamada S, Uchida H, Kajiyama H, Nagino M, Kodera Y, Gotoh M.	Clinical characteristics and surgical outcomes of retroperitoneal tumors: a comprehensive data collection from multiple departments.	Int J Clin Oncol	Epub ahead of print		2020
Murakami N, Sakai T, Arai E, Muramatsu H, Ichikawa D, Asai S, Shimoyama Y, Ishiguro N, Takahashi Y, Okuno Y, Nishida Y	Targetable driver mutations in multicentric reticulohistiocytosis.	Haematologica	105(2)	e61–e64	2020
Koike H, Nishida Y , Shinomura T, Zhuo L, Hamada S, Ikuta K, Ito K, Kimata K, Ushida T, Ishiguro N.	Forced Expression of KIAA1199, a Novel Hyaluronidase, Inhibits Tumorigenicity of Low-Grade Chondrosarcoma.	J Orthop Res	Epub ahead of print		2020
Desmoid Tumor Working Group. (Alman B, Nishida Y , et al)	The management of desmoid tumours: A joint global	Eur J Cancer.	127	96-107	2020

	consensus-based guideline approach for adult and paediatric patients.				
Hamada S, Nishida Y , Takanari K, Ota T, Urakawa H, Ikuta K, Sakai T, Tsukushi S, Kamei Y, Ishiguro N.	Functional evaluation following deltoid muscle resection in patients with soft tissue sarcoma	Jap J Clin Oncol	pii	hyaa 039	2020
Shimizu K, Hamada S, Sakai T, Koike H, Yoshida M, Nishida Y	Efficacy of low dose chemotherapy with methotrexate and vinblastine for patients with extra-abdominal desmoid-type fibromatosis : A systematic review.	Jpn J Clin Oncol	50(4)	419-424	2020
Miller DT, Cortés-Ciriano I, Pillay N, Hirbe AC, Snuderl M, Bui MM, Piculell K, Al-Ibraheemi A, Dickson BC, Hart J, Jones K, Jordan JT, Kim RH, Lindsay D, Nishida Y , Ullrich NJ, Wang X, Park PJ, Flanagan AM.	Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs.	Genes (Basel)	11(4)	E387	2020
本間 明宏 .	進行上顎洞癌に対する超選択的動注化学療法を併用した放射線治療による新規治療法開発に関する研究.	日耳鼻	122	844-847	2019
Monden N, Asakage T, Kiyota N, Homma A , Matsuura K, Hanai N, Kodaira T, Zenda S, Fujii H, Tahara M, Yokota T, Akimoto T, Iwae S, Onitsuka T, Ogawa T, Okano S, Takahashi S, Shimizu Y, Yonezawa K, Hayashi R.	A review of head and neck cancer staging system in the TNM classification of malignant tumors (eighth edition).	Jpn J Clin Oncol.	49	589-595	2019
Hanai N, Asakage T, Kiyota N, Homma A , Hayashi R.	Controversies in relation to neck management in N0 early oral tongue cancer.	Jpn J Clin Oncol	49	297-305	2019
amauchi S, Yokota T, Mizumachi T, Onozawa Y, Ogawa H, Onoe T, Kamijo T, Iida Y, Nishimura T, Onitsuka T, Yasui H, Homma A .	Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.	Int J Clin Oncol.	24	468-475	2019
Ogata M, Satake H, Ogata T, Hatachi Y, Hara S, Hirota S , Yasui H.	Reduction and escalation in the dose of sunitinib were adequately effective against gastrointestinal stromal tumor of the small intestine: a case report.	Intern Med.	58	3243-3246	2019
Iemura Y, Katsushima H, Kataoka TR, Hirota S , Shimada T.	An unusual case of duodenal gastrointestinal stromal tumour combined with the neuronal elements.	Pathol Int.	69	414-419	2019
Katayanagi S, Yokoyama T, Makuuchi Y, Osakabe H, Iwamoto H, Sumi T, Hirano H, Katsumata K, Tsuchida A, Hirota S , Kawachi S	Long-term survival after multidisciplinary treatment including surgery for metachronous metastases of small intestinal gastrointestinal	Am J Case Rep.	20	1942-1948	2019

	stromal tumors after curative resection: a case report.				
Nishida T, Sakai Y, Takagi M, Ozaka M, Kitagawa Y, Kurokawa Y, Masuzawa T, Naito Y, Kagimura T, Hirota S	Adherence to the guidelines and the pathological diagnosis of high-risk gastrointestinal stromal tumors in the real world.	Gastric Cancer	23	118-125	2020
Saito Y, Takahashi T, Obata Y, Nishida T, Ohkubo S, Nakagawa F, Serada S, Fujimoto M, Ohkawara T, Nishigaki T, Sugase T, Koh M, Ishida T, Tanaka K, Miyazaki Y, Makino T, Kurokawa Y, Nakajima K, Yamasaki M, Hirota S , Naka T, Mori M, Doki Y.	TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours.	Br J Cancer.	122	658-667	2020
Arima J, Hiramatsu M, Taniguchi K, Kobayashi T, Tsunematsu I, Kagota S, Sakane J, Suzuki Y, Hirota S .	Multiple gastrointestinal stromal tumors caused by a novel germline <i>KIT</i> gene mutation (Asp820Gly): A case report and literature review.	Gastric Cancer.	Epub ahead of print		
Shinto E, Omata J, Sikina A, Sekizawa A, Kajiwarra Y, Hayashi K, Hashiguchi Y , Hase K, Ueno H.	Predictive immunohistochemical features for tumour response to chemoradiotherapy in rectal cancer.	BJS open.	4(2)	301-309	2020
Hayama T, Hashiguchi Y , Okada Y, Ono K, Nemoto K, Shimada R, et al.	Significance of the 7th postoperative day neutrophil-to-lymphocyte ratio in colorectal cancer.	Int J Colorectal Dis.	35(1)	119-124	2020
Hashiguchi Y , Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et al.	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer.	Int J Clin Oncol.	25(1)	1-42	2020
Hayama T, Hashiguchi Y , Okamoto K, Okada Y, Ono K, Shimada R, et al.	G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer.	Int J Colorectal Dis.	34(8)	1491-1496	2019
Ueno H, Kanemitsu Y, Sekine S, Ishiguro M, Ito E, Hashiguchi Y , et al.	A Multicenter Study of the Prognostic Value of Desmoplastic Reaction Categorization in Stage II Colorectal Cancer.	Am J Surg Pathol.	43(8)	1015-1022	2019
Motoi F, Satoi S, Honda G, Wada K, Shinchi H, Matsumoto I, Sho M , Tsuchida A, Unno M;	A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.	J Gastroenterol	54(2)	194-203	2019
Motoi F, Murakami Y, Okada KI, Matsumoto I, Uemura K, Satoi S, Sho M , Honda G, Fukumoto T, Yanagimoto H, Kinoshita S, Kurata M, Aoki S, Mizuma M, Yamaue H, Unno M;	Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma.	World J Surg	43(2)	634-641	2019
Nagai M, Sho M , Akahori T, Nishiwada S, Nakagawa K,	Risk Factors for Late-Onset Gastrointestinal Hemorrhage	World J Surg	43(2)	626-633	2019

Nakamura K, Tanaka T, Nishiofuku H, Kichikawa K, Ikeda N.	After Pancreatoduodenectomy for Pancreatic Cancer.				
Nakamura K, Sho M , Akahori T, Nagai M, Nishiwada S, Nakagawa K, Tanaka T, Kichikawa K, Tamamoto T, Hasegawa M, Mitoro A, Yoshiji H, Ikeda N.	A Comparison Between Plastic and Metallic Biliary Stent Placement in Patients Receiving Preoperative Neoadjuvant Chemoradiotherapy for Resectable Pancreatic Cancer.	World J Surg	43(2)	642-648	2019
Wakatsuki K, Matsumoto S, Migita K, Kunishige T, Nakade H, Miyao S, Sho M .	Prognostic value of the fibrinogen-to-platelet ratio as an inflammatory and coagulative index in patients with gastric cancer.	Surg Today	49(4)	334-342	2019
Tsujimoto A, Ueda T, Kuge H, Inoue T, Obara S, Nakamoto T, Sasaki Y, Nakamura Y, Koyama F, Sho M .	Long-term survival after adrenal metastasectomy from colorectal cancer: a report of two cases.	Surg Case Rep.	5(1)	61	2019
Akahori T, Sho M , Yanagimoto H, Satoi S, Nagai M, Nishiwada S, Nakagawa K, Nakamura K, Yamamoto T, Hirooka S, Yamaki S, Ikeda N.	Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma	Oncologist.			2019
Matsumoto S, Wakatsuki K, Migita K, Nakade H, Kunishige T, Miyao S, Sho M .	Anastomotic leakage following retrosternal pull-up.	Langenbecks Arch Surg.	404(3)	335-341	2019
Migita K, Matsumoto S, Wakatsuki K, Kunishige T, Nakade H, Miyao S, Sho M .	Postoperative Serum C-Reactive Protein Level Predicts Long-Term Outcomes in Stage I Gastric Cancer.	J Surg Res.	242:	323-331	2019
Nakagawa K, Sho M , Akahori T, Nagai M, Nakamura K, Takagi T, Tanaka T, Nishiofuku H, Ohbayashi C, Kichikawa K, Ikeda N.	Significance of the inflammation-based prognostic score in recurrent pancreatic cancer.	Pancreatology.	19(5)	722-728	2019
Kamitani N, Migita K, Matsumoto S, Wakatsuki K, Kunishige T, Nakade H, Miyao S, Sho M .	Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy.	Surg Today.	49(12)	1022-1028	2019
Sasaki Y, Hokuto D, Inoue T, Nomi T, Yoshikawa T, Matsuo Y, Koyama F, Sho M .	Significance of Herpesvirus Entry Mediator Expression in Human Colorectal Liver Metastasis.	Ann Surg Oncol.	26(12)	3982-3989	2019
Yoshikawa T, Nomi T, Sakai K, Hayakawa M, Hokuto D, Matsuo Y, Sho M , Matsumoto M.	Ischaemia-reperfusion injury with Pringle's maneuver induces unusually large von Willebrand factor multimers after hepatectomy.	Thromb Res.	183	20-27	2019
Motoi F, Kosuge T, Ueno H, Yamaue H, Satoi S, Sho M , Honda G, Matsumoto I, Wada K, Furuse J, Matsuyama Y, Unno M;	Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer	Jpn J Clin Oncol.	49(2)	190-194	2019

	(Prep-02/JSAP05).				
Nagakawa Y, Sahara Y, Hosokawa Y, Murakami Y, Yamaue H, Satoi S, Unno M, Isaji S, Endo I, Sho M , Fujii T, Takishita C, Hijikata Y, Suzuki S, Kawachi S, Katsumata K, Ohta T, Nagakawa T, Tsuchida A.	Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.	Ann Surg Oncol.	26(6)	1629-1636	2019
Aoki S, Motoi F, Murakami Y, Sho M , Satoi S, Honda G, Uemura K, Okada KI, Matsumoto I, Nagai M, Yanagimoto H, Kurata M, Fukumoto T, Mizuma M, Yamaue H, Unno M;	Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.	BMC Cancer	19(1)	252	2019
Nishiguchi Y, Fujiwara-Tani R, Sasaki T, Luo Y, Ohmori H, Kishi S, Mori S, Goto K, Yasui W, Sho M , Kuniyasu H.	Targeting claudin-4 enhances CDDP-chemosensitivity in gastric cancer.	Oncotarget.	10(22)	2189-2202	2019
Shioyama E, Mitoro A, Ogawa H, Kubo T, Ozutsumi T, Kitagawa K, Yoshikawa M, Ueda S, Akahori T, Marugami NA, Hatakeyama K, Yamao J, Sho M , Ohbayashi C, Yoshiji H.	A pancreatic mucinous cystic neoplasm undergoing intriguing morphological changes over time and associated with recurrent pancreatitis: A case report.	Medicine (Baltimore).	98(28)	e16435	2019
Mizuno S, Kato H, Yamaue H, Fujii T, Satoi S, Saiura A, Murakami Y, Sho M , Yamamoto M, Isaji S.	Left-sided Portal Hypertension After Pancreaticoduodenectomy With Resection of the Portal Vein/Superior Mesenteric Vein Confluence in Patients With Pancreatic Cancer: A Project Study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery.	Ann Surg.			2019
Tanaka T, Sato T, Nishiofuku H, Masada T, Tatsumoto S, Marugami N, Otsuji T, Kanno M, Koyama F, Sho M , Kichikawa K.	Selective TACE with irinotecan-loaded 40µm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study.	BMC Cancer.	19(1)	758	2019
Shibuya K, Jang JY, Satoi S, Sho M , Yamada S, Kawai M, Kim H, Kim SC, Heo JS, Yoon YS, Park JS, Hwang HK, Yoshioka I, Shimokawa T, Yamaue H, Fujii T.	The efficacy of polyglycolic acid felt reinforcement in preventing postoperative pancreatic fistula after pancreaticojejunostomy in patients with main pancreatic duct less than 3 mm in diameter and soft pancreas undergoing pancreaticoduodenectomy (PLANET-PJ trial): study protocol for a multicentre randomized phase III trial in Japan and Korea.	Trials	20(1)	490	2019
Sasaki T, Fujiwara-Tani R, Kishi S, Mori S, Luo Y, Ohmori H,	Targeting claudin-4 enhances chemosensitivity of pancreatic	Cancer Med.	8(15):	6700-670	2019

Kawahara I, Goto K, Nishiguchi Y, Mori T, Sho M , Kondo M, Kuniyasu H.	ductal carcinomas.			8	
Ohtsuka T, Nagakawa Y, Toyama H, Takeda Y, Maeda A, Kumamoto Y, Nakamura Y, Hashida K, Honda G, Fukuzawa K, Toyoda E, Tanabe M, Gotohda N, Matsumoto I, Ryu T, Uyama I, Kojima T, Unno M, Ichikawa D, Inoue Y, Matsukawa H, Sudo T, Takaori K, Yamaue H, Eguchi S, Tahara M, Shinzeki M, Eguchi H, Kurata M, Morimoto M, Hayashi H, Marubashi S, Inomata M, Kimura K, Amaya K, Sho M , Yoshida R, Murata A, Yoshitomi H, Hakamada K, Yasunaga M, Abe N, Hioki M, Tsuchiya M, Misawa T, Seyama Y, Noshiro H, Sakamoto E, Hasegawa K, Kawabata Y, Uchida Y, Kameyama S, Ko S, Takao T, Kitahara K, Nakahira S, Baba H, Watanabe M, Yamamoto M, Nakamura M.	A multicenter prospective registration study on laparoscopic pancreatectomy in Japan: report on the assessment of 1,429 patients.	J Hepato biliary Pancre at Sci.			2019
Nishiguchi Y, Oue N, Fujiwara-Tani R, Sasaki T, Ohmori H, Kishi S, Mori S, Mori T, Ikeda N, Matsumoto S, Wakatsuki K, Luo Y, Yasui W, Sho M , Kuniyasu H.	Role of Metastasis-Related Genes in Cisplatin Chemoresistance in Gastric Cancer.	Int J Mol Sci.			

「厚生労働科学研究費における倫理審査及び利益相反の管理の状況に関する報告について
(平成26年4月14日科発0414第5号)」の別紙に定める様式(参考)

年 月 日

厚生労働大臣
(国立医薬品食品衛生研究所長) 殿
(国立保健医療科学院長)

機関名

所属研究機関長 職 名

氏 名 _____ 印

次の職員の(元号) 年度厚生労働科学研究費の調査研究における、倫理審査状況及び利益相反等の管理については以下のとおりです。

1. 研究事業名 _____
2. 研究課題名 _____
3. 研究者名 (所属部局・職名) _____
(氏名・フリガナ) _____

4. 倫理審査の状況

	該当性の有無 有 無	左記で該当がある場合のみ記入(1)		
		審査済み	審査した機関	未審査(2)
ヒトゲノム・遺伝子解析研究に関する倫理指針				
遺伝子治療等臨床研究に関する指針				
人を対象とする医学系研究に関する倫理指針(3)				
厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針				
その他、該当する倫理指針があれば記入すること (指針の名称: _____)				

(1) 当該研究者が当該研究を実施するに当たり遵守すべき倫理指針に関する倫理委員会の審査が済んでいる場合は、「審査済み」にチェックし一部若しくは全部の審査が完了していない場合は、「未審査」にチェックすること。

その他(特記事項)

(2) 未審査の場合は、その理由を記載すること。

(3) 廃止前の「疫学研究に関する倫理指針」や「臨床研究に関する倫理指針」に準拠する場合は、当該項目に記入すること。

5. 厚生労働分野の研究活動における不正行為への対応について

研究倫理教育の受講状況	受講	未受講
-------------	----	-----

6. 利益相反の管理

当研究機関におけるCOIの管理に関する規定の策定	有 無 (無の場合はその理由: _____)
当研究機関におけるCOI委員会設置の有無	有 無 (無の場合は委託先機関: _____)
当研究に係るCOIについての報告・審査の有無	有 無 (無の場合はその理由: _____)
当研究に係るCOIについての指導・管理の有無	有 無 (有の場合はその内容: _____)

(留意事項) ・該当する にチェックを入れること。
・分担研究者の所属する機関の長も作成すること。